Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Current Leases: 2019-2025

Historic Current Leases for Lifecore Biomedical (LFCR) over the last 6 years, with Feb 2025 value amounting to $4.0 million.

  • Lifecore Biomedical's Current Leases fell 4.64% to $4.0 million in Q1 2025 from the same period last year, while for Feb 2025 it was $4.0 million, marking a year-over-year decrease of 4.64%. This contributed to the annual value of $4.0 million for FY2024, which is 212.05% up from last year.
  • Latest data reveals that Lifecore Biomedical reported Current Leases of $4.0 million as of Q1 2025, which was down 3.64% from $4.1 million recorded in Q4 2024.
  • In the past 5 years, Lifecore Biomedical's Current Leases ranged from a high of $4.4 million in Q1 2022 and a low of $977,000 during Q2 2021.
  • Moreover, its 3-year median value for Current Leases was $4.0 million (2024), whereas its average is $2.8 million.
  • In the last 5 years, Lifecore Biomedical's Current Leases plummeted by 77.91% in 2021 and then spiked by 347.08% in 2022.
  • Lifecore Biomedical's Current Leases (Quarterly) stood at $1.2 million in 2021, then skyrocketed by 255.83% to $4.3 million in 2022, then tumbled by 72.47% to $1.2 million in 2023, then spiked by 245.01% to $4.1 million in 2024, then fell by 4.64% to $4.0 million in 2025.
  • Its last three reported values are $4.0 million in Q1 2025, $4.1 million for Q4 2024, and $4.1 million during Q3 2024.